Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM26-2198 in Healthy Volunteers and Adult Patients With Atopic Dermatitis
NCT05859724Phase 1Terminated
- Sponsor
- Yellow Jersey Therapeutics
- Start
- May 2023
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing Placebo with NM26-2198 (2 arms). Primary endpoint: Treatment Emergent Adverse Events at Day 85. Started May 2023; status: terminated.
02
Drugs
NM26
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05859724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05859724.